<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03943888</url>
  </required_header>
  <id_info>
    <org_study_id>1904-149-1029</org_study_id>
    <nct_id>NCT03943888</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children</brief_title>
  <official_title>Pharmacokinetic-pharmacodynamic Analysis of Reversal of Rocuronium-induced Neuromuscular Blockade by Sugammadex in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Food and Drug Safety, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study administers sugammadex sodium to pediatric patients under general anesthesia with
      rocuronium. Pharmacokinetic and pharmacodynamic analysis are performed based on plasma
      concentration of sugammadex sodium and monitoring of neuromuscular blockade.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study enrolls pediatric patients undergoing surgery under general anesthesia with need
      for early reversal of neuromuscular blockade, aged between 2 and 18 years old.

      After routine anesthetic induction with 1% propofol and 0.6mg/kg of rocuronium, maintenance
      of anesthesia with total intravenous anesthesia is commenced. 15 minutes after rocuronium
      administration, 2 or 4 or 8mg/kg of sugammadex sodium or conventional neuromuscular reversal
      agent is administered according to randomization table.

      For neuromuscular monitoring, train-of-four (TOF) count and T4/T1 ratio are monitored, with
      recording of the time to recovery of the T4/T1 ratio to 0.7, 0.8 and 0.9.

      For pharmacokinetic analysis, patient blood sample is obtained before / 2 min after
      rocuronium administration, before / 2min / 5min / 15min / 60min / 120min / 240min / 480min
      after sugammadex administration. Plasma concentration of rocuronium and sugammadex sodium are
      analyzed via high-performance liquid chromatography with mass spectrometric detection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Actual">February 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 20, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neuromuscular recovery</measure>
    <time_frame>up to 30 minutes to 1 hour</time_frame>
    <description>Time to recovery of train-of-four T4/T1 ratio to 90% after sugammadex sodium or neuromuscular reversal agent administration up to 30 minutes to 1 hour.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations</measure>
    <time_frame>From anesthetic induction to 480 minutes after sugammadex administration</time_frame>
    <description>Plasma concentrations of rocuronium and sugammadex sodium</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Anesthesia, General</condition>
  <condition>Neuromuscular Blockade</condition>
  <arm_group>
    <arm_group_label>Sugammadex 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 2mg/kg of sugammadex 15 minutes after rocuronium administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 4mg/kg of sugammadex 15 minutes after rocuronium administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugammadex 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administer 8mg/kg of sugammadex 15 minutes after rocuronium administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional reversal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administer conventional neuromuscular reversal agent (0.02mg/kg of atropine and 0.03mg/kg of neostigmine) 15 minutes after rocuronium administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection 2mg/kg</intervention_name>
    <description>Intravenous injection of 2mg/kg of sugammadex sodium 15 minutes after rocuronium administration</description>
    <arm_group_label>Sugammadex 2mg</arm_group_label>
    <other_name>Bridion 2mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection 4mg/kg</intervention_name>
    <description>Intravenous injection of 4mg/kg of sugammadex sodium 15 minutes after rocuronium administration</description>
    <arm_group_label>Sugammadex 4mg</arm_group_label>
    <other_name>Bridion 4mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugammadex Injection 8mg/kg</intervention_name>
    <description>Intravenous injection of 8mg/kg of sugammadex sodium 15 minutes after rocuronium administration</description>
    <arm_group_label>Sugammadex 8mg</arm_group_label>
    <other_name>Bridion 8mg/kg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neuromuscular reversal agent injection</intervention_name>
    <description>Intravenous injection of 0.02mg/kg of atropine and 0.03mg/kg of neostigmine</description>
    <arm_group_label>Conventional reversal</arm_group_label>
    <other_name>Atropine and neostigmine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All of below

          -  Pediatric patients undergoing surgery under general anesthesia with requirement of
             early reversal of neuromuscular blockade

          -  Aged between 2 and 17

          -  American Society of Anesthesiologists Physical Status Classification 1 and 2

        Exclusion Criteria: Any of below

          -  One or more legal guardian declines to enroll in the study

          -  History of hypersensitivity to any anesthetic agents including rocuronium

          -  Presence of underlying cardiovascular or genitourinary disease

          -  Under usage of neuromuscular blocking agents before surgery

          -  Under usage of drugs influencing the effect of neuromuscular blocking agents

          -  History of malignant hyperthermia

          -  Anticipation of massive hemorrhage during surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee-Soo Kim, M.D, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNUH</name>
      <address>
        <city>Seoul</city>
        <state>Jongro Gu</state>
        <zip>15710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005 Oct;103(4):695-703.</citation>
    <PMID>16192761</PMID>
  </reference>
  <reference>
    <citation>Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, Viby-Mogensen J. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006 Apr;104(4):667-74.</citation>
    <PMID>16571960</PMID>
  </reference>
  <reference>
    <citation>Sparr HJ, Vermeyen KM, Beaufort AM, Rietbergen H, Proost JH, Saldien V, Velik-Salchner C, Wierda JM. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. Anesthesiology. 2007 May;106(5):935-43.</citation>
    <PMID>17457124</PMID>
  </reference>
  <reference>
    <citation>Ploeger BA, Smeets J, Strougo A, Drenth HJ, Ruigt G, Houwing N, Danhof M. Pharmacokinetic-pharmacodynamic model for the reversal of neuromuscular blockade by sugammadex. Anesthesiology. 2009 Jan;110(1):95-105. doi: 10.1097/ALN.0b013e318190bc32.</citation>
    <PMID>19104176</PMID>
  </reference>
  <reference>
    <citation>Won YJ, Lim BG, Lee DK, Kim H, Kong MH, Lee IO. Sugammadex for reversal of rocuronium-induced neuromuscular blockade in pediatric patients: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Aug;95(34):e4678. doi: 10.1097/MD.0000000000004678.</citation>
    <PMID>27559972</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 6, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee-Soo Kim</investigator_full_name>
    <investigator_title>MD, PhD, Professor</investigator_title>
  </responsible_party>
  <keyword>sugammadex</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>pediatric anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

